Clinuvel Pharmaceuticals eyes Nasdaq switch and ASX delisting after decade of unbroken profit
Melbourne pharma Clinuvel is weighing a restructure into a US holding company listed only on Nasdaq and an ASX exit, weeks after completing a Nasdaq ADS uplisting, alongside a tenth straight annual profit.